RU2144017C1 - Tritium highly marked cyclosporin a - Google Patents

Tritium highly marked cyclosporin a Download PDF

Info

Publication number
RU2144017C1
RU2144017C1 RU98123848A RU98123848A RU2144017C1 RU 2144017 C1 RU2144017 C1 RU 2144017C1 RU 98123848 A RU98123848 A RU 98123848A RU 98123848 A RU98123848 A RU 98123848A RU 2144017 C1 RU2144017 C1 RU 2144017C1
Authority
RU
Russia
Prior art keywords
tritium
cyclosporin
ampoule
reaction
highly
Prior art date
Application number
RU98123848A
Other languages
Russian (ru)
Inventor
В.П. Шевченко
Н.Ф. Мясоедов
И.Ю. Нагаев
Original Assignee
Институт молекулярной генетики РАН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Институт молекулярной генетики РАН filed Critical Институт молекулярной генетики РАН
Priority to RU98123848A priority Critical patent/RU2144017C1/en
Application granted granted Critical
Publication of RU2144017C1 publication Critical patent/RU2144017C1/en

Links

Abstract

FIELD: organic chemistry, medicobiological research. SUBSTANCE: described is new tritium highly marked physiologically active cyclosporin A compound of formula I

Description

Изобретение относится к области органической химии и может быть использовано при медикобиологических исследованиях. The invention relates to the field of organic chemistry and can be used in biomedical research.

Современные методы исследования физиологически активных соединений требуют использования их в виде высокомеченных производных. Modern methods for the study of physiologically active compounds require their use in the form of highly labeled derivatives.

Циклоспорин A - вещество общей формулы

Figure 00000003

(The Merck Index an encyclopedia of chemicals druds and biolodicals Eleventth Edition and 12-th 1989-1996 NJ U.S.A.),
является физиологически активным соединением. Циклоспорин A не описан в виде высокомеченного тритием производного.Cyclosporin A - a substance of the General formula
Figure 00000003

(The Merck Index an encyclopedia of chemicals druds and biolodicals Eleventth Edition and 12-th 1989-1996 NJ USA),
is a physiologically active compound. Cyclosporin A is not described as a high tritium derivative.

Задачей, решаемой настоящим изобретением, явилось расширение ассортимента высокомеченных физиологически активных соединений. Задача решена тем, что впервые получен высокомеченный третием циклоспорин A. The problem solved by the present invention was the expansion of the range of highly labeled physiologically active compounds. The problem is solved in that the first highly labeled third cyclosporin A.

Ниже приведены примеры, иллюстрирующие изобретение. The following are examples illustrating the invention.

Пример 1. В реакционную ампулу помещена 12,1 мг циклоспорина A, 30,8 мг 5% PdO/Al2O3, 52,0 мг PdO. Напускали газообразный тритий до давления 400 гПа, и при охлаждении жидким азотом средней части ампулы смесь нагревали при 80oC в течение 10 мин. При этом образующаяся при восстановлении окиси палладия стопроцентная тритиевая вода конденсировалась в средней части ампулы. Далее зону, содержащую активированный катализатор, вакуумировали при температуре 20oC 10 мин. При этом основная часть адсорбированного на катализаторе трития удалялась и не гидрировала двойные связи циклоспорина A. Затем реакцию вели следующим образом. Снимали охлаждение со средней части ампулы и охлаждали жидким азотом нижнюю часть ампулы. При этом тритиевая вода перегонялась в смесь катализатора и вещества, ампулу снимали с установки, в реакционную ампулу впрыскивали 100 мкл смеси диоксана с триэтиламином (9:1), ампулу запаивали и реакцию вели при 150oC 60 мин. Затем содержимое ампулы замораживали жидким азотом, ампулу вскрывали, катализатор отфильтровывали и промывали метанолом (5х0,5 мл). Общая радиоактивность реакционного раствора после изотопного обмена 13,2 Ки, без тритиевой воды - 0,7 Ки, после ТСХ - 140 мКи, после первой ВЭЖХ - 45 мКи, после второй ВЭЖХ - 8 мКи (радиохимическая чистота выше 97%). Выход меченого препарата 60 - 65%, с молярной радиоактивностью - 1 Ки/ммоль.Example 1. 12.1 mg of cyclosporin A, 30.8 mg of 5% PdO / Al 2 O 3 , 52.0 mg of PdO were placed in a reaction vial. Tritium gas was injected to a pressure of 400 hPa, and when the middle part of the ampoule was cooled with liquid nitrogen, the mixture was heated at 80 ° C for 10 minutes. In this case, 100% tritium water formed during the reduction of palladium oxide condensed in the middle part of the ampoule. Next, the zone containing the activated catalyst was evacuated at a temperature of 20 ° C. for 10 minutes. In this case, the bulk of tritium adsorbed on the catalyst was removed and did not hydrogenate cyclosporin A double bonds. Then, the reaction was carried out as follows. The cooling was removed from the middle part of the ampoule and the lower part of the ampoule was cooled with liquid nitrogen. In this case, tritium water was distilled into a mixture of a catalyst and a substance, the ampoule was removed from the installation, 100 μl of a mixture of dioxane and triethylamine (9: 1) were injected into the reaction ampoule, the ampoule was sealed, and the reaction was carried out at 150 ° C for 60 min. Then, the contents of the ampoule were frozen with liquid nitrogen, the ampoule was opened, the catalyst was filtered off and washed with methanol (5x0.5 ml). The total radioactivity of the reaction solution after an isotopic exchange of 13.2 Ci, without tritium water - 0.7 Ci, after TLC - 140 mCi, after the first HPLC - 45 mCi, after the second HPLC - 8 mCi (radiochemical purity higher than 97%). The yield of labeled preparation is 60–65%, with a molar radioactivity of 1 Ci / mmol.

Меченый препарат очищали хроматографическими методами: ТСХ: (А) Ацетон-этилацетат - 50% уксусная кислота (2:1:5) Rf 0,82, (Б) трет-бутанол-метилэтилкетон-вода-аммиак (6,6: 5,0: 2,5:2,5) Rf (0,91; (В) бензол-диоксан (4: 1) Rf 0,36; (Г) хлороформ-диоксан (4:1) Rf 0,65; (Д) гексан-изо-пропиловый спирт (4:1) Rf 0,53. ВЭЖХ: (Ж) Saporon SGX, 5 мкм, 3,3х150 мм, метанол-50 мМ аммонийфосфатный буфер (pH 4,5) (85:15), V - 2 мл, 60oC, время удержания - 15,41 мин; (И) Silasorb C18, 13 мкм, 10х250 мм, метанол-вода-уксусная кислота (85:15:0,1), V - 2 мл, 60oC, время удерживания - 15,85 мин; (К) Nucleosil C18, 5 мкм, 2х75 мм, метанол - 50 мМ буфер (pH 2,7) (82:18), V - 0,1 мл/мин, 50oC, время удерживания - 9,05 мин; (М) Nucleosil C18, 5 мкм, 2х75 мм, метанол-буфер (pH 4,5) (87:13), V - 0,1 мл/мин, 60oC, время удерживания - 5,52 мин.The labeled preparation was purified by chromatographic methods: TLC: (A) Acetone-ethyl acetate - 50% acetic acid (2: 1: 5) Rf 0.82, (B) tert-butanol-methyl ethyl ketone-water-ammonia (6.6: 5, 0: 2.5: 2.5) Rf (0.91; (B) benzene-dioxane (4: 1) Rf 0.36; (D) chloroform-dioxane (4: 1) Rf 0.65; (D ) hexane-isopropyl alcohol (4: 1) Rf 0.53. HPLC: (W) Saporon SGX, 5 μm, 3.3x150 mm, methanol-50 mM ammonium phosphate buffer (pH 4.5) (85:15) , V - 2 ml, 60 o C, retention time - 15.41 min; (I) Silasorb C 18 , 13 μm, 10x250 mm, methanol-water-acetic acid (85: 15: 0.1), V - 2 ml, 60 o C, retention time - 15.85 min; (K) Nucleosil C 18 , 5 μm, 2x75 mm, methanol - 50 mm buffer (pH 2.7) (82:18), V - 0.1 ml / min, 5 0 o C, retention time - 9.05 min; (M) Nucleosil C 18 , 5 μm, 2x75 mm, methanol buffer (pH 4.5) (87:13), V - 0.1 ml / min, 60 o C, retention time - 5.52 minutes

Пример 2. В реакционную ампулу помещали 12,4 мг циклоспорина A, 31 мг 5% PdO/Al2O3, 51,7 мг PdO. Напускали газообразный тритий до давления 450 гПа, и при охлаждении жидким азотом средней части ампулы смесь нагревали при 70oC в течение 10 мин. При этом образующаяся при восстановлении окиси палладия стопроцентная тритиева вода конденсировалась в средней части ампулы. Далее зону, содержащую активированный катализатор, вакуумировали при температуре 25oC 5 мин. При этом основная часть адсорбированного на катализаторе трития удалялась и не гидрировала двойные связи циклоспорина A. Затем реакцию вели следующим образом. Снимали охлаждение со средней части ампулы и охлаждали жидким азотом нижнюю часть ампулы. При этом тритиевая вода перегонялась в смесь катализатора и вещества, ампулу снимали с установки, в реакционную ампулу впрыскивали 100 мкл смеси диоксана с триэтиламином (9:1), ампулу запаивали и реакцию вели при 180oC 40 мин. Затем содержимое ампулы замораживали жидким азотом, ампулу вскрывали, катализатор отфильтровывали и промывали метанолом (5х0,5 мм). Общая радиоактивность реакционного раствора после изотопного обмена 13 Ки, без тритиевой воды - 0,8 Ки, после ТСХ - 180 мКи, после первой ВЭЖХ - 60 мКи, после второй ВЭЖХ - 30 мКи (радиохимическая чистота выше 97%). Выход меченого препарата 50 - 55%, с молярной радиоактивностью - 4 Ки/ммоль.Example 2. 12.4 mg of cyclosporin A, 31 mg of 5% PdO / Al 2 O 3 , 51.7 mg of PdO were placed in a reaction vial. Tritium gas was injected to a pressure of 450 hPa, and when the middle part of the ampule was cooled with liquid nitrogen, the mixture was heated at 70 ° C for 10 minutes. In this case, 100% tritium water formed during the reduction of palladium oxide condensed in the middle part of the ampoule. Next, the zone containing the activated catalyst was evacuated at a temperature of 25 ° C. for 5 minutes. In this case, the bulk of tritium adsorbed on the catalyst was removed and did not hydrogenate cyclosporin A double bonds. Then, the reaction was carried out as follows. The cooling was removed from the middle part of the ampoule and the lower part of the ampoule was cooled with liquid nitrogen. In this case, tritium water was distilled into a mixture of catalyst and substance, the ampoule was removed from the installation, 100 μl of a mixture of dioxane and triethylamine (9: 1) was injected into the reaction ampoule, the ampoule was sealed, and the reaction was carried out at 180 ° C for 40 min. Then the contents of the ampoule were frozen with liquid nitrogen, the ampoule was opened, the catalyst was filtered off and washed with methanol (5x0.5 mm). The total radioactivity of the reaction solution after an isotope exchange of 13 Ci, without tritium water - 0.8 Ci, after TLC - 180 mCi, after the first HPLC - 60 mCi, after the second HPLC - 30 mCi (radiochemical purity higher than 97%). The output of the labeled drug is 50 - 55%, with a molar radioactivity of 4 Ci / mmol.

Таким образом, впервые получен высокомеченный тритием циклоспорин A. Thus, the first highly labeled tritium cyclosporin A.

Claims (1)

Высокомеченный тритием циклоспорин А формулы
Figure 00000004
Highly Tritiated Cyclosporin A Formulas
Figure 00000004
RU98123848A 1998-12-21 1998-12-21 Tritium highly marked cyclosporin a RU2144017C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU98123848A RU2144017C1 (en) 1998-12-21 1998-12-21 Tritium highly marked cyclosporin a

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU98123848A RU2144017C1 (en) 1998-12-21 1998-12-21 Tritium highly marked cyclosporin a

Publications (1)

Publication Number Publication Date
RU2144017C1 true RU2144017C1 (en) 2000-01-10

Family

ID=20214102

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98123848A RU2144017C1 (en) 1998-12-21 1998-12-21 Tritium highly marked cyclosporin a

Country Status (1)

Country Link
RU (1) RU2144017C1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sigma. 1988. C.337. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders

Similar Documents

Publication Publication Date Title
EP0605622B1 (en) Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
DK255184D0 (en) PROCEDURE FOR THE MANUFACTURING OF OPTICALLY ACTIVE CARBAZOLD DERIVATIVES, NEW R-AND S-CARBAZOLD DERIVATIVES, AND MEDICINES CONTAINING THESE COMPOUNDS
JPS61225159A (en) Complex of technetium 99m with propyleneamine oxime
Peck et al. Streptomyces antibiotics. VII. The structure of streptidine
WO1992005154A1 (en) Novel nitrogen-sulfur ligands useful in radiographic imaging agents
RU2144017C1 (en) Tritium highly marked cyclosporin a
SK11832003A3 (en) Pregabalin lactose conjugates
RU2164803C2 (en) Thrombin inhibitor-containing aqueous solution for nonparenteral administration showing stability at storage
EP0561523A2 (en) Sugar compound, sialic acid-containing sugar chains' biosynthesis inhibitor, production process thereof and intermediate
Sheha et al. Brain delivery of HIV protease inhibitors
RU2143431C1 (en) 2-1(propylene-4,6-dimethyl-8-oxymethyl)octyl-('3-oxy- 4',5',6'-trimethyl-6-ene)heptyl ketone and method of preparing thereof
Bird Amoxicillin
RU2191187C1 (en) Monofluoroquinolones highly labeled with tritium
EP0133887A1 (en) Water-soluble rifampicin derivatives
RU2183610C1 (en) Ethylacetamide highly labeled with tritium
US5908931A (en) Preorganized hexadentate ligands useful in radiographic imaging agents
RU2137773C1 (en) Tritium high-labeled 6-amino-1,5-dihydro-4h-imidazo- [4,5-c]-pyridine-4-on
US4201866A (en) O-Hemi-succinate of propranolol
RU2206562C1 (en) Highly tritium-labeled 7-(4'-dimethylaminophenyl)-7-oxo-2,4-heptadiene hydroxamic acid
RU2132331C1 (en) Furan derivatives highly labeled with tritium
KR102207372B1 (en) Stabilizer for Radiopharmaceuticals and Radiopharmaceutical composition comprising the same
CN111205284A (en) Synthetic method of palonosetron hydrochloride related substance A
RU2268256C1 (en) Tritium high-labeled [3h]-(e)-n-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-noneneamide
RU2143416C1 (en) Tritium highly marked coenzyme a or acetyl coenzyme a
RU2151136C1 (en) Highly marked substituted carbamates

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20111222